Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014;14 Suppl 5(Suppl 5):S4.
doi: 10.1186/1471-2334-14-S5-S4. Epub 2014 Sep 5.

Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV

Silvia Odolini, Silvia Amadasi, Carlo Cerini, Mariarosaria Giralda, Paola Nasta, Francesco Castelli
Observational Study

Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV

Silvia Odolini et al. BMC Infect Dis. 2014.

Abstract

Background: HIV infection leads to a faster progression of liver disease in subjects infected with HCV, as compared with HCV mono-infected patients. Previous reports suggest that sustained virological response (SVR) rates are lower in HIV/HCV coinfection than in HCV monoinfection. We aimed to compare SVR rates of these two populations.

Methods: We retrospectively analyzed clinical, biochemical and virological data of HCV and HIV/HCV infected patients with HCV genotypes 2 and 3 who started anti-HCV treatment between March 2004 and November 2012, at a single large center. Intention-to-treat (ITT) and per-protocol (PP) analysis were performed. Univariate and multivariate logistic regression analyses were performed to assess predictors of SVR.

Results: 461 patients were analyzed: 307 (66.6%) males, 76 (16.5%) infected with HIV. Several differences at baseline between HCV monoinfected and HIV/HCV coinfected patients were observed. HCV monoinfected group was characterized by higher prevalence of genotype 2 (53% vs 5.3%), higher baseline HCV viral load (50% vs 35%), shorter mean duration of treatment (19 vs 41 weeks), more frequent use of peginterferon alfa-2a (84.5% vs 69.7%), lower prevalence of cirrhosis (6% vs 31.6%). Globally, SVR was achieved by 353 (76.6%) patients and 321 (83.8%) in the PP analysis. No statistically relevant differences were found in SVR rates between the two groups, either in ITT [78.2% (n = 301/385) vs 68.4% (n = 52/76), p =0.066, respectively] than in PP analysis [83.6% (n = 276/330) vs 84.9% (n = 45/53), p = 0.8].

Conclusions: Higher baseline viral loads and interruption of peginterferon and/or ribavirin were associated with a poor outcome of anti-HCV treatment while HIV infection was not related to major or minor probability to achieve SVR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rate of undetectability in monoinfected and coinfected patients (ITT analysis).
Figure 2
Figure 2
Rate of undetectability in monoinfected and coinfected patients (PP analysis).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC. Optimizing treatment in HIV/HCV coinfection. Dig Liver Dis. 2013;14:S355–S362. - PubMed
    1. Barcaui HS, Tavares GC, May SB, Brandão-Mello CE, Amendola Pires MM, Feijò Barroso P. Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil. PLoS One. 2013;14(7):e67734. doi: 10.1371/journal.pone.0067734. - DOI - PMC - PubMed
    1. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infectious Diseases. 2012;14(Suppl 2):S2. doi: 10.1186/1471-2334-12-S2-S2. - DOI - PMC - PubMed
    1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;14:392–420. - PubMed
    1. Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J. the GESIDA HIV/HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;14(5):728–36. doi: 10.1093/cid/cis500. - DOI - PubMed

Publication types

MeSH terms